ARID2 and neoplasm: Whole exome sequencing (WES) identified a KEAP1/STK11 co-mutation with loss of function for both genes, a MAP2K1 activation, and an ARID2 loss of function, as well as a low tumor mutational burden (TMB) with no actionable mutation (4.4 mut/Mb) (Supplementary Table 1).